Dogwood Therapeutics, Inc. (DWTX): Nasdaq/NYSE listing notice — Virios receives Nasdaq bid price deficiency notice; has 180 days to regain compliance

Dogwood Therapeutics, Inc.

Nasdaq notice on Nov 1, 2022: bid price below $1.00 for 30 consecutive business days.
Compliance deadline is May 1, 2023; can cure by closing at $1.00+ for 10 consecutive days.
If not compliant, may qualify for second 180-day period or face delisting and possible appeal.
Company will monitor bid price and may consider options to regain compliance.
Common stock continues to trade under VIRI on Nasdaq Capital Market for now.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Dogwood Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

November 1, 2022, Virios Therapeutics, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). The Notice has no effect at this time on the Company’s common stock, which continues to trade on The Nasdaq Cap

View on SEC.gov

Browse all listing & compliance notices →

Dogwood Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-22-015975

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.